P. Zuck et al., Bacteriological eradication of Streptococcus pneumonia from patients with acute exacerbations of chronic bronchitis: Cefuroxime axetil versus cefixime, INT J CL PR, 53(6), 1999, pp. 437-443
The bacteriological eradication rates of Streptococcus pneumoniae from sput
um of patients experiencing acute exacerbations of chronic bronchitis (WHO
definition) have been compared following therapy with either cefuroxime axe
til 250 mg b.d. or cefixime 200 mg b.d. All patients were hospitalised for
an acute exacerbation of chronic bronchitis. The study design was a multice
ntre, double-blind, randomised, parallel group with patients giving written
informed consent initially. Patients were recruited to the study if they m
et the WHO definition of chronic bronchitis, were aged 30-75 years and had
a high probability of S. pneumoniae infection based on initial sputum Gram
stain. All S. pneumoniae isolates were serotyped and susceptibility tested
at the National Reference Centre, Paris. S. pneumoniae was eradicated more
rapidly following cefuroxime axetil administration than after cefixime and
this difference was statistically significant (p=0.002) at 2-4 days post-tr
eatment. Clinical endpoints showed a similar trend - 94% response to cefuro
xime axetil compared with 71% response to cefixime (RR 6.39.1). Cefuroxime
eradicated S. pneumoniae significantly more rapidly than cefixime and patie
nts in the cefuroxime axetil arm had favourable clinical criteria. The data
suggest that focused antibacterial studies may be helpful in evaluating an
tibiotics in acute exacerbation of chronic bronchitis.